Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

Recruiting now · Phase 4

Conditions studied: Factor VIII Deficiency

In brief

The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximately 12 months.

Key facts

Study ID

NCT06941870

Run by

Sanofi

People needed

35

Starts

2025-09-23

Expected to finish

2027-10-25

Last updated by the study team

2025-11-18

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Orthopedic Institute for Children- Site Number : 8400009 — Los Angeles, California, United States (enrolling)
• Innovative Hematology, Inc.- Site Number : 8400006 — Indianapolis, Indiana, United States (enrolling)
• University of Iowa- Site Number : 8400004 — Iowa City, Iowa, United States (enrolling)
• Ohio State University Hospital East- Site Number : 8400001 — Columbus, Ohio, United States (enrolling)
• Investigational Site Number : 1240003 — Hamilton, Ontario, Canada (enrolling)
• Investigational Site Number : 1240004 — Hamilton, Ontario, Canada (enrolling)
• Investigational Site Number : 3920003 — Kawasaki, Kanagawa, Japan (enrolling)
• Investigational Site Number : 3920002 — Hiroshima, Japan (enrolling)
• Investigational Site Number : 3920001 — Saitama, Japan (enrolling)
• Investigational Site Number : 3920004 — Tokyo, Japan (enrolling)
• Investigational Site Number : 1580003 — Kaohsiung City, Taiwan (enrolling)
• Investigational Site Number : 1580001 — Taichung, Taiwan (enrolling)
• Investigational Site Number : 1580002 — Taipei, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.